Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 17,643 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Open Label Clear all
Completed Phase 1 Interventional

Study of Safety and Tolerability of EO2002 in the Treatment of Corneal Edema

NCT04894110
View directory record Official record
Conditions
Corneal Edema, Corneal Endothelial Dysfunction, Corneal Endothelial Dystrophy, Fuchs Dystrophy, Fuchs Endothelial Corneal Dystrophy, Pseudophakic Bullous Keratopathy, Bullous Keratopathy, Endothelial Dysfunction, Moderate Corneal Endothelial Decompensation
Interventions
EO2002, EO2002 low dose, EO2002 mid dose, EO2002 high dose
Biological
Lead sponsor
Emmecell
Industry
Eligibility
21 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
8
States / cities
Greater Los Angeles, California • San Diego, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2025 · Synced Oct 25, 2026, 9:19 PM EDT
Terminated Phase 2 Interventional

GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC

NCT03417882
View directory record Official record
Conditions
Metastatic NSCLC
Interventions
GRN-1201 + Pembrolizumab
Biological
Lead sponsor
BrightPath Biotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
11
States / cities
Orange, California • Aurora, Colorado • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 25, 2026, 9:19 PM EDT
Completed No phase listed Observational

Long-Term Follow-Up Gene Therapy Study for Leber Congenital Amaurosis OPTIRPE65 (Retinal Dystrophy Associated With Defects in RPE65)

NCT02946879
View directory record Official record
Conditions
Leber Congenital Amaurosis (LCA), Eye Diseases, Eye Diseases, Hereditary, Retinal Diseases
Interventions
AAV OPTIRPE65
Biological
Lead sponsor
MeiraGTx UK II Ltd
Industry
Eligibility
3 Years to 100 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Volunteers to Investigate the Effects of Ketoconazole on the Pharmacokinetics of NKTR-118

NCT01520896
View directory record Official record
Conditions
Bioavailability, Healthy Volunteers, Drug- Drug Interactions
Interventions
NKTR-118, Ketoconazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 1 Interventional Results available

Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

NCT01055496
View directory record Official record
Conditions
Lymphoma, B-Cell
Interventions
inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone, inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
10
States / cities
Gainesville, Florida • Philadelphia, Pennsylvania • Houston, Texas + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 2 Interventional Results available

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

NCT03664960
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
Interventions
AK002
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 3 Interventional

A Study for the Treatment of Mania Associated With Bipolar I Disorder in Children and Adolescents

NCT00195780
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Divalproex Sodium (Depakote ER)
Drug
Lead sponsor
Abbott
Industry
Eligibility
10 Years to 17 Years
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
29
States / cities
San Diego, California • San Marcos, California • Altamonte Springs, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2007 · Synced Oct 25, 2026, 9:19 PM EDT
Not listed Phase 2 Interventional

Rho Kinase (ROCK) Inhibitor in Tauopathies - 1

NCT04734379
View directory record Official record
Conditions
Progressive Supranuclear Palsy, Corticobasal Syndrome
Interventions
Fasudil
Drug
Lead sponsor
Woolsey Pharmaceuticals
Industry
Eligibility
35 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to See if Platelet Transfusion Stop or Lessen the Effect of the Drug on Platelets

NCT01744288
View directory record Official record
Conditions
Inhibition on Platelet Aggregation
Interventions
Ticagrelor, Clopidogrel, ASA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years
Enrollment
258 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 1 Interventional

A Phase 1, Open-Label Study of Latanoprost Acid Plasma Concentrations in Pediatric and Adult Glaucoma Patients Treated With Latanoprost.

NCT00638742
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
latanoprost
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
0 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Artesia, California • Atlanta, Georgia • North Dartmouth, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Trial to Assess Long-term Lacosamide (LCM) Monotherapy Use and Safety of LCM Monotherapy and Adjunctive Therapy for Partial-onset Seizures

NCT00530855
View directory record Official record
Conditions
Epilepsy
Interventions
Lacosamide
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
16 Years to 70 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
77
States / cities
Alabaster, Alabama • Birmingham, Alabama • Northport, Alabama + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

A Study of Mirvetuximab Soravtansine vs. Investigator's Choice (IC) of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha (FRα) Expression

NCT04209855
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older · Female only
Enrollment
453 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
78
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 2 Interventional

Liposomal Amikacin for Inhalation (LAI) in the Treatment of Mycobacterium Abscessus Lung Disease

NCT03038178
View directory record Official record
Conditions
Mycobacterium Infections, Nontuberculous, Mycobacteria, Atypical
Interventions
LAI plus multi-drug regimen
Drug
Lead sponsor
Kevin Winthrop
Other
Eligibility
12 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Portland, Oregon • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2020 · Synced Oct 25, 2026, 9:19 PM EDT
Active, not recruiting Phase 1 Interventional

Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents

NCT02264678
View directory record Official record
Conditions
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
Interventions
Administration of ceralasertib, Administration of ceralasertib in combination with olaparib, Administation of ceralasertib in combination with durvalumab, Administration of ceralasertib monotherapy, Administration of ceralasertib and olaparib, Administration of ceralasertib and durvalumab, Administration of ceralasertib in combination with AZD5305, Administration of ceralasertib in combination with carboplatin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
8
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 9:19 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study of SC-007 in Subjects With Advanced Cancer

NCT03253185
View directory record Official record
Conditions
Colorectal Cancer (CRC), Gastric Cancer
Interventions
SC-007
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
7
States / cities
Los Angeles, California • Rochester, Minnesota • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327

NCT04069143
View directory record Official record
Conditions
Healthy Participants, Idiopathic Pulmonary Fibrosis (IPF)
Interventions
18F-BMS-986327
Diagnostic Test
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

NCT01325415
View directory record Official record
Conditions
Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions
NKTR-118, moxifloxacin, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 2Phase 3 Interventional

Open Label Clinical Trial of Vitamin D in Children With Autism

NCT01535508
View directory record Official record
Conditions
Autism, Vitamin D Deficiency
Interventions
Liquid Vitamin D
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
3 Years to 8 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2019 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 1 Interventional

Evaluating the Safety and Tolerability of the Poly-ADP Ribose (PARP) Inhibitor With FOLFIRI in Subjects With Solid Tumor

NCT01123876
View directory record Official record
Conditions
Gastric Cancer
Interventions
Veliparib
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years to 99 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Scottsdale, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2021 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis)

NCT04432376
View directory record Official record
Conditions
Otomycosis
Interventions
miconazole 2% oil, vehicle oil
Drug
Lead sponsor
Hill Dermaceuticals, Inc.
Industry
Eligibility
7 Years and older
Enrollment
382 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
12
States / cities
Chula Vista, California • La Jolla, California • Roseville, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2024 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

NCT04655040
View directory record Official record
Conditions
Healthy Participants
Interventions
Caffeine, Ritlecitinib
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Not applicable Interventional Results available

Early Feasibility Study of the Reia Vaginal Pessary

NCT04275089
View directory record Official record
Conditions
Pelvic Organ Prolapse, Prolapse
Interventions
Reia Vaginal Pessary
Device
Lead sponsor
Reia, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jul 28, 2023 · Synced Oct 25, 2026, 9:19 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Mild or Moderate Renal Impairment

NCT03011450
View directory record Official record
Conditions
Severe Hypertriglyceridemia
Interventions
K-877, Fenofibrate, Placebo (for K-877)
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
471 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
129
States / cities
Birmingham, Alabama • Hamilton, Alabama • Huntsville, Alabama + 109 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 25, 2026, 9:19 PM EDT